| 臺大學術典藏 |
2020-12-02T02:33:07Z |
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer
|
Chen Z.; Huang K.-Y.; Ling Y.; Goto M.; Duan H.-Q.; Tong X.-H.; Liu Y.-L.; Cheng Y.-Y.; Morris-Natschke S.L.; Pan-Chyr Yang; Yang S.-L.; Lee K.-H.; Chen Z.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-09-28T07:04:37Z |
Nationwide epidemiology and prognosis of dialysis-requiring acute kidney injury (NEP-AKI-D) study: Design and methods
|
Lee K.-H.; Huang C.-T.; Shiao C.-C.; Wu P.-C.; Lin J.-H.; Pan H.-C.; Yang Y.-F.; Lai T.-S.; Huang T.-M.; Wu C.-H.; Yang W.-S.; Wu C.-J.; Kao C.-C.; Sun C.-Y.; Lin C.-Y.; Chen T.-C.; Hu F.-C.; Liou H.-H.; Lu K.-C.; Chien K.-L.; Wang J.-J.; Kan W.-C.; Kuo F.-C.; Lin H.Y.-H.; Chen C.-M.; You Z.-H.; Tsai J.-P.; Weng C.-J.; Chen H.-Y.; Chang C.-F.; Hsu W.-D.; Wu M.-S.; Huang C.-C.; Wu K.-D.; on behalf of the Taiwan Consortium for Acute Kidney Injury Renal Diseases (CAKs) |
| 臺大學術典藏 |
2020-06-27T06:40:12Z |
Reduction of human-to-pig cellular response by alteration of porcine MHC with human HLA DPW0401 exogenes
|
Lee J.-M.;Tu C.-F.;Yang P.-W.;Lee K.-H.;Tsuji K.;Tsai M.-K.;Chen R.J.;Hu C.-Y.;Hsieh R.-P.;Tai H.-C.;Bor-Luen Chiang;Weng C.-N.;Lee Y.-C.;Lee C.-J.; Lee J.-M.; Tu C.-F.; Yang P.-W.; Lee K.-H.; Tsuji K.; Tsai M.-K.; Chen R.J.; Hu C.-Y.; Hsieh R.-P.; Tai H.-C.; BOR-LUEN CHIANG; Weng C.-N.; Lee Y.-C.; Lee C.-J. |
| 臺大學術典藏 |
2020-06-17T03:01:51Z |
Antitumor agents 283. Further elaboration of Desmosdumotin C analogs as potent antitumor agents: Activation of spindle assembly checkpoint as possible mode of action
|
Nakagawa-Goto K. ;Wu P.-C. ;Bastow K.F. ;Yang S.-C. ;Sung-Liang Yu ;Chen H.-Y. ;Lin J.-C. ;Goto M. ;Morris-Natschke S.L. ;Yang P.-C. ;Lee K.-H.; Nakagawa-Goto K.; Wu P.-C.; Bastow K.F.; Yang S.-C.; SUNG-LIANG YU; Chen H.-Y.; Lin J.-C.; Goto M.; Morris-Natschke S.L.; Yang P.-C.; Lee K.-H. |
| 臺大學術典藏 |
2020-06-17T03:01:50Z |
Antitumor agents 288: Design, synthesis, SAR, and biological studies of novel heteroatom-incorporated antofine and cryptopleurine analogues as potent and selective antitumor agents
|
Yang X. ;Shi Q. ;Yang S.-C. ;Chen C.-Y. ;Sung-Liang Yu ;Bastow K.F. ;Morris-Natschke S.L. ;Wu P.-C. ;Lai C.-Y. ;Wu T.-S. ;Pan S.-L. ;Teng C.-M. ;Lin J.-C. ;Yang P.-C. ;Lee K.-H.; Yang X.; Shi Q.; Yang S.-C.; Chen C.-Y.; SUNG-LIANG YU; Bastow K.F.; Morris-Natschke S.L.; Wu P.-C.; Lai C.-Y.; Wu T.-S.; Pan S.-L.; Teng C.-M.; Lin J.-C.; Yang P.-C.; Lee K.-H. |
| 臺大學術典藏 |
2020-06-17T03:00:43Z |
Reduction of human-to-pig cellular response by alteration of porcine MHC with human HLA DPW0401 exogenes
|
Lee J.-M.;Tu C.-F.;Yang P.-W.;Lee K.-H.;Tsuji K.;Tsai M.-K.;Chen R.J.;Hu C.-Y.;Hsieh R.-P.;Hao-Chih Tai;Chiang B.-L.;Weng C.-N.;Lee Y.-C.;Lee C.-J.; Lee J.-M.; Tu C.-F.; Yang P.-W.; Lee K.-H.; Tsuji K.; Tsai M.-K.; Chen R.J.; Hu C.-Y.; Hsieh R.-P.; HAO-CHIH TAI; Chiang B.-L.; Weng C.-N.; Lee Y.-C.; Lee C.-J. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
|
Sequist L.V;Chih-Hsin Yang;Yamamoto N;O'Byrne K;Hirsh V;Mok T;Geater S.L;Orlov S;Tsai C.-M;Boyer M;Su W.-C;Bennouna J;Kato T;Gorbunova V;Lee K.H;Shah R;Massey D;Zazulina V;Shahidi M;Schuler M.; Sequist L.V; CHIH-HSIN YANG; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials
|
Sequist L.V.;Zazulina V;Shahidi M;Massey D;Kato T;Lee K.H;Su W.-C;Boyer M;Mok T;Orlov S;Bennouna J;Hirsh V;Gorbunova V;Tsai C.-M;Lee K.Y;Geater S.L;Huang Y;Lu S;Feng J;O'Byrne K;Hu C.-P;Zhou C;Yamamoto N;Popat S;Sebastian M;Schuler M;Wu Y.-L;Chih-Hsin Yang; CHIH-HSIN YANG; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. |
| 臺大學術典藏 |
2020-05-26T09:26:45Z |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
|
Paz-Ares L.;Zazulina V;Massey D;Kim M;Shahidi M;Tsai C.-M;Laurie S.A;K?lbeck K;Arvis C.D;Kim D.-W;Laskin J;Kim S.-W;Shi Y;Lu S;Lee K.H;Chih-Hsin Yang;Hirsh V;Mok T;Boyer M;Zhang L;O'Byrne K;Tan E.-H;Park K; Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
|
Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:35Z |
Phase III, randomized, placebo-controlled, double-blind trial of motesanib (AMG-706) in combination with paclitaxel and carboplatin in east asian patients with advanced nonsquamous non-small-cell lung cancer
|
Chih-Hsin Yang;Lin C.-B;Lee K.-H;Cho E.K;Park K;Tanaka H;Ichinose Y;Yamada K;Kato T;Kaneda H;Hayashi H;Nakagawa K;Yoh K;Hida T;Oshita F;Yoshioka H;Hara K;Asato T;Kubota K; Kubota K; Asato T; Hara K; Yoshioka H; Oshita F; Hida T; Yoh K; Nakagawa K; Hayashi H; Kaneda H; Kato T; Yamada K; Ichinose Y; Tanaka H; Park K; Cho E.K; Lee K.-H; Lin C.-B; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:27Z |
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
|
Park K.;Paz-Ares L; Chih-Hsin Yang;M?rten A;Peil B;Mok T;Boyer M;O'Byrne K;Yamamoto N;Hirsh V;Schuler M;Barrios C.H;Kato T;Tsai C.-M;Lee K.H;Zhang L;Orlov S;Geater S.L;Tan E.-H;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
|
Popat S.;Kerstein D;Haney J;Gupta N;Tiseo M;Gettinger S.N;Spira A;Ghosh S;Califano R;Felip E;Morabito A;Griesinger F;Bearz A;Kim D.-W;Garcia Campelo R;Delmonte A;Gridelli C;Lee K.H;Chang G.-C;Li J.Y.-C;Hochmair M.J;Lee J.-S;Han J.-Y;Chih-Hsin Yang;Ahn M.-J;Kim H.R;Camidge D.R; Camidge D.R; Kim H.R; Ahn M.-J; CHIH-HSIN YANG; Han J.-Y; Lee J.-S; Hochmair M.J; Li J.Y.-C; Chang G.-C; Lee K.H; Gridelli C; Delmonte A; Garcia Campelo R; Kim D.-W; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger S.N; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
|
Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
|
Schuler M;Paz-Ares L;Sequist L.V;Hirsh V;Lee K.H;Wu Y.-L;Lu S;Zhou C;Feng J;Ellis S.H;Samuelsen C.H;Tang W;M?rten A;Ehrnrooth E;Park K;Chih-Hsin Yang; Schuler M; Paz-Ares L; Sequist L.V; Hirsh V; Lee K.H; Wu Y.-L; Lu S; Zhou C; Feng J; Ellis S.H; Samuelsen C.H; Tang W; Märten A; Ehrnrooth E; Park K; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-�] and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
|
Paz-Ares L; Kim T.M; Vicente D; Felip E; Lee D.H; Lee K.H; Chia-Chi Lin; Flor M.J; Di Nicola M; Alvarez R.M; Dussault I; Helwig C; Ojalvo L.S; Gulley J.L; Cho B.C. |
| 臺大學術典藏 |
2020-05-25T06:51:42Z |
Treating HR+/HER2? breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression
|
Yeo W;Ueno T;Lin C.-H;Liu Q;Lee K.-H;Leung R;Naito Y;Park Y.H;Im S.-A;Li H;Yap Y.S;Yen-Shen Lu;The Asian Breast Cancer Cooperative Group; Yeo W; Ueno T; Lin C.-H; Liu Q; Lee K.-H; Leung R; Naito Y; Park Y.H; Im S.-A; Li H; Yap Y.S; YEN-SHEN LU; The Asian Breast Cancer Cooperative Group |
| 臺大學術典藏 |
2020-05-25T06:51:42Z |
Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population
|
YEN-SHEN LU; Asian Breast Cancer Cooperative Group; Cheng A.-L; Huang C.-S; Hu F.-C; Tan B; Han W; Leung R; Huang S.-M; Li H; Kwong A; Ueno T; Yeo W; Naito Y; Im S.-A; Lee K.-H; Yap Y.S; Lin C.-H; Lin C.-H;Yap Y.S;Lee K.-H;Im S.-A;Naito Y;Yeo W;Ueno T;Kwong A;Li H;Huang S.-M;Leung R;Han W;Tan B;Hu F.-C;Huang C.-S;Cheng A.-L;Yen-Shen Lu;Asian Breast Cancer Cooperative Group |
| 臺大學術典藏 |
2020-05-04T07:44:11Z |
Data-driven IoT applications design for smart city and smart buildings
|
Lin, K.-J.; CHI-SHENG SHIH; Chou, J.-J.; Shih, C.-S.;Lee, K.-H.;Chou, J.-J.;Lin, K.-J.; Shih, C.-S.; Lee, K.-H. |
| 臺大學術典藏 |
2020-05-04T07:27:14Z |
On cooperative energy-efficient P2P live streaming system for mobile hotspots
|
Chang, C.-Y.; CHENG-FU CHOU; Lee, K.-H.; Chou, C.-F.; Chen, M.-H.; Chen, M.-H.;Chou, C.-F.;Lee, K.-H.;Chang, C.-Y. |
| 臺大學術典藏 |
2020-04-27T08:45:04Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; Yang J.C.H.; Wang J.; Babu K.G.; Douillard J.-Y.; Yoshino T.; Peters S.; Ahn H.K.; Kim T.-Y.; Ahn Y.C.; Senan S.; CHIA-HSIEN CHENG; Chua K.L.M.; Alip A.; Nakayama Y.; Park K.;Vansteenkiste J.;Lee K.H.;Pentheroudakis G.;Zhou C.;Prabhash K.;Seto T.;Voon P.J.;Tan D.S.W.;Yang J.C.H.;Wang J.;Babu K.G.;Nakayama Y.;Alip A.;Chua K.L.M.;Chia-Hsien Cheng;Senan S.;Ahn Y.C.;Kim T.-Y.;Ahn H.K.;Peters S.;Yoshino T.;Douillard J.-Y. |
| 臺大學術典藏 |
2020-03-31T03:59:58Z |
Successful generation of transgenic pigs for human decay-accelerating factor and human leucocyte antigen DQ
|
Tu C.-F.;Hsieh S.-L.;Jang-Ming Lee;Yang L.-L.;Sato T.;Lee K.-H.;Weng C.-N.;Mao S.J.T.;Tsuji K.;Lee C.-J.; Tu C.-F.; Hsieh S.-L.; JANG-MING LEE; Yang L.-L.; Sato T.; Lee K.-H.; Weng C.-N.; Mao S.J.T.; Tsuji K.; Lee C.-J. |
| 臺大學術典藏 |
2020-03-31T03:59:52Z |
Reduction of human-to-pig cellular response by alteration of porcine MHC with human HLA DPW0401 exogenes
|
JANG-MING LEE; Tu C.-F.; Yang P.-W.; Lee K.-H.; Tsuji K.; Tsai M.-K.; Chen R.J.; Hu C.-Y.; Hsieh R.-P.; Tai H.-C.; Chiang B.-L.; Weng C.-N.; Lee Y.-C.; Lee C.-J.; Jang-Ming Lee;Tu C.-F.;Yang P.-W.;Lee K.-H.;Tsuji K.;Tsai M.-K.;Chen R.J.;Hu C.-Y.;Hsieh R.-P.;Tai H.-C.;Chiang B.-L.;Weng C.-N.;Lee Y.-C.;Lee C.-J. |
| 臺大學術典藏 |
2020-03-23T07:18:47Z |
Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population
|
Im S.-A.; Naito Y.; Yeo W.; Ueno T.; Kwong A.; Li H.; Huang S.-M.; Leung R.; Han W.; Tan B.; Hu F.-C.; CHIUN-SHENG HUANG; Cheng A.-L.; Lu Y.-S.; Asian Breast Cancer Cooperative Group; Lee K.-H.; Yap Y.S.; Lin C.-H. |
| 臺大學術典藏 |
2020-02-26T01:32:42Z |
Breast tumor classification based on image sequence analysis during compression
|
Lee, K.-H.;Chou, Y.-H.;Chen, C.-M.;Li, P.-C.Chung-Ming Chen; Lee, K.-H.; Chou, Y.-H.; Chen, C.-M.; Li, P.-C.; CHUNG-MING CHEN |
